Sixth GAVI Board Meeting, 17 October 2001, Ottawa, Canada
3. Opening Window 3 of the Vaccine Fund to support R&D
research and development vary according to the kind of problem to be
addressed. For example, the need for disease burden studies is an
obvious gap in R&D funding. However, development of new vaccines, or
adaptation of existing vaccines for developing country settings such
as a stabilized measles vaccine are more complex issues for
consideration and will need additional work.
pharmaceutical companies should not necessarily be ruled out as long
as it goes to support clinical development of a vaccine targeted for
developing countries and no commercial incentive exists for that
cannot obligate the Vaccine Fund to purchase future products, we must
consider the effect on companies investment in product development if
there is no assured market.
specific funding decisions are taken by the Board, the various 'push'
and 'pull' options should be well defined, e.g., whether research
grants, advance purchase, tax incentives or other tools would be the
most effective in accelerating vaccine development. If a
pharmaceutical company is to be funded then there would have to be a
quid pro quo agreed to assure access for developing countries.
that the proposed guidelines should be taken forward for final
approval by the Board, subject to modification based on the issues
raised in the discussion.